ESR1 and breast carcinoma: These conjugate compounds have potential application for further development as antineoplastic agents, (possibly modulating more than a single molecular target–in this case tubulin), in the treatment of both ER positive and ER negative breast cancers and these chemical classes of structures may be useful as scaffolds to be considered for multitarget drugs in future drug development studies.